|
|
||||||||
1 Departments of Internal Medicine, 2 Pharmaceutical Sciences, 3 Pathology and 4 Surgery, University of Arkansas for Medical Sciences and Central Arkansas Veterans Healthcare System, Little Rock, Arkansas 72205
| |
ABSTRACT |
|---|
|
|
|---|
Hyperhomocysteinemia (Hhe), linked to cardiovascular disease by epidemiological studies, may be an important factor in adverse cardiac remodeling in hypertension. Specifically, convergence of myocardial and vascular alterations promoted by Hhe and hypertension may exacerbate cardiac remodeling and myocardial dysfunction. We studied male spontaneously hypertensive rats fed one of three diets: control, intermediate Hhe inducing, or severe Hhe inducing. After 10 wk of dietary intervention, cardiac function was assessed in vitro, and cardiac and coronary arteriolar remodeling were monitored by histomorphometric, immunohistochemical, and biochemical techniques. Results showed that Hhe induced diastolic dysfunction, as characterized by the diastolic pressure-volume curve, without significant changes in baseline systolic function. Perivascular collagen levels were increased by Hhe, and there was an increase in left ventricular hydroxyproline levels. Myocyte size was not affected. Coronary arteriolar wall thickness increased with Hhe due to smooth muscle hyperplasia. Mast cells increased in parallel with Hhe and collagen accumulation. In summary, 10 wk of Hhe caused coronary arteriolar remodeling, myocardial collagen deposition, and diastolic dysfunction in hypertensive rats.
homocysteine; diastolic dysfunction; collagen; interstitium; arteriole
| |
INTRODUCTION |
|---|
|
|
|---|
HYPERTENSION and other pressure-overload conditions, such as aortic stenosis, result in pathological left ventricular (LV) hypertrophy (LVH). This LVH, a result of adverse cardiac remodeling, is characterized by a combination of myocyte hypertrophy and nonmyocyte cell proliferation with increased deposition of collagen, culminating in increased fibrosis disproportionate to myocyte hypertrophy (39). These changes initially lead to deleterious effects on diastolic function (due to increased myocardial stiffness) and subsequently to depressed contractile function. In addition, coronary arteriolar remodeling with medial thickening and perivascular fibrosis also accompanies adverse cardiac remodeling in hypertension and can contribute to myocyte loss and myocardial dysfunction (21, 27).
The role of hyperhomocysteinemia (Hhe) in the pathogenesis of cardiovascular disease (CVD) has been the subject of active epidemiological investigation. Cross-sectional, retrospective case-control studies and prospective studies have shown an association between Hhe and CVD, including myocardial infarction and stroke. Several pathophysiological mechanisms have been postulated to explain the link between Hhe and atherothrombotic CVD, including endothelial dysfunction, endothelial cytotoxicity, lipid peroxidation, smooth muscle cell proliferation, increased collagen production, and platelet aggregation (18, 24). In addition to these vascular effects, Hhe has been associated with clinical LVH. A study by Blacher and co-workers (1) examined the relationship between high homocysteine levels and LVH in patients with end-stage renal disease. The results of this retrospective study suggested that there is a positive correlation between LV mass index and plasma homocysteine, even after adjustment for age, sex, systolic blood pressure, and hematocrit.
In light of the prevailing hypotheses regarding macrovascular pathogenic mechanisms of Hhe, it seems possible that Hhe may also act to exacerbate the myocardial and coronary arteriolar remodeling and myocardial collagen deposition caused by hypertension. These structural changes would result in adverse effects on cardiac function and potentially contribute to increased cardiovascular morbidity and mortality. Our experiments, which examined the effects of high homocysteine levels on cardiac structure and function in spontaneously hypertensive rats (SHRs), demonstrated that Hhe causes adverse remodeling of the myocardium and coronary arterioles in hypertension, leading to diastolic dysfunction.
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
Animals. All procedures in this study were approved by the Institutional Animal Care and Use Committee of the University of Arkansas for Medical Sciences. Three-month-old male SHRs (300-325 g) were purchased from Harlan Sprague Dawley (Indianapolis, IN) and maintained in our institutional Division of Laboratory Animal Medicine facility on a 12:12-h light-dark cycle with free access to chow and water. After 7-10 days of acclimatization to this facility, the animals were randomized into three groups.
Animals in each group were then allowed free access to one of three purified amino acid diets (Harlan Teklad, Indianapolis, IN) for 10 wk: control, intermediate Hhe (IH) inducing, or severe Hhe (SH) inducing. The control and SH diets have been described by others (30). The IH diet was designed by supplementing the control diet with homocystine, the disulfide form of homocysteine (9 g/kg), and the SH diet was deficient in folate, choline, and methionine but supplemented with homocystine (4.5 g/kg) (30). Differences among the diets are shown in Table 1. The IH and SH diets were designed to produce intermediate (30-100 µmol/l) and severe (>100 µmol/l) Hhe, respectively, in the rats.
|
Langendorff-perfused hearts.
This procedure is routinely used in our laboratories (14).
Hearts were isolated from rats in each of the treatment groups after 10 wk of dietary intervention and perfused via the aorta with an
oxygenated Krebs-Henseleit solution (37°C) of the following composition (in mM): 118.0 NaCl, 27.1 NaHCO3, 3.7 KCl, 1.8 CaCl2, 1.2 MgCl2, 1.0 KH2PO4, and 11.1 glucose. The flow rate was set at 7.0 ml · g
heart
1 · min
1, a
value similar to that observed when flow is examined at a constant
pressure of 80 mmHg; coronary pressure was monitored continuously by a
Statham pressure transducer. Both atria were removed, and the
ventricles were paced electrically at 250 beats/min by platinum contact
electrodes positioned on the interventricular septum. A fluid-filled
balloon catheter (connected to a pressure transducer) was placed in the
LV to measure intraventricular pressure under isovolumic conditions,
and the heart was enclosed in a humidified, temperature-controlled
chamber. Contractile function was monitored by measuring the peak
pressure and maximum rates of contraction and relaxation
(+dP/dtmax and
dP/dtmax) at various preload balloon volumes (10-80 µl, a range that elicited maximum contractility in all preparations). These balloon volumes represent the volume of
fluid within the balloon and do not include the volume of the balloon
itself, which varied very slightly from 48 to 52 µl. In addition to
the polygraph recording, all data were digitized and analyzed with the
use of acquisition and analysis software (CODAS, DataQ Instruments;
Akron, OH).
Morphometric measurement of collagen volume fraction and coronary arteriolar remodeling. Morphometric measurements were done as previously described (29). Sections (5 µm) of formalin-fixed, paraffin-embedded tissue were stained with picrosirius red to identify fibrillar collagen (13). Digital images of stained sections were acquired with a charge-coupled device camera (Hamamatsu; Bridgewater, NJ) attached to a Zeiss Axioskop microscope (Zeiss; Thornwood, NY). The integrated image analysis software packages Axiovision 1 and KS300 version 3.0 (Zeiss) were used for morphometric analysis. Perivascular collagen was measured in 50- to 200-µm vessels (10-15 vessels/section) and expressed relative to the vessel luminal area. Interstitial collagen was analyzed in 30-40 microscopic fields/section, and the interstitial collagen volume fraction was calculated as the percentage of collagen-stained interstitial regions relative to the total ventricular area. The arteriolar wall-to-lumen ratio was analyzed in 50- to 200-µm vessels (10-15 vessels/section).
Hydroxyproline assay. Hydroxyproline was assayed using a procedure described by others (5, 31). The LV apex was cut into small pieces and dried to constant weight in an oven set at 65°C. The samples were then allowed to cool to room temperature, and, after being weighed, the dried tissues were transferred into 1.5-ml Eppendorf tubes. HCl (6 N, 200 µl) was added to each tube to hydrolyze the sample by overnight incubation at 105°C. After the tubes cooled, 200 µl of 6 N NaOH were added to each tube, followed by 600 µl isopropanol, and the samples were mixed well. An equal amount of each sample (10 µl) was aliquoted from the aqueous layer into individual borosilicate glass tubes and diluted with acetate-citrate-isopropanol buffer to a final volume of 400 µl; 100 µl of fresh oxidant solution were added, and the samples were mixed and allowed a 5-min incubation period. Ehrlich's reagent solution (1.3 ml) was added, and the samples were mixed and incubated at 60°C for 30 min. After samples were cooled, the absorbance was measured at 558 nm against a blank. The reagent blank was prepared by substituting 60 µl of buffer for the sample in the reaction mixture. Hydroxyproline concentration, expressed as micrograms per milligram of heart weight, was calculated from the absorbance reading of each sample with the use of a calibration curve prepared by assaying standard solutions.
Immunostaining for
-smooth muscle actin.
Heart tissue was fixed in formalin and embedded in paraffin. Sections
(5 µm) were prepared, and immunohistochemistry was performed using
anti-smooth muscle actin (Dako; Carpinteria, CA) with appropriate controls. The image analysis system discussed above was used for morphometric analysis.
Estimation of mast cell number. Sections of heart were stained with toluidine blue to identify mast cells by metachromasia (26). A pathologist counted the total number of mast cells in each section in a blinded fashion.
Statistical analysis. Data were evaluated by ANOVA with a Student-Newman-Keuls post hoc test using SigmaStat (SPSS; Chicago, IL). The criterion for significance was a P value of <0.05. Data are reported as means ± SE.
| |
RESULTS |
|---|
|
|
|---|
We used the SHR model of genetic hypertension to determine whether short-term Hhe exacerbates myocardial and coronary arteriolar remodeling and alters cardiac function in the hypertensive heart.
Animal model of Hhe.
Table 2 shows parameter values for the
three groups after 10 wk of treatment with the amino acid-defined diets
detailed in Table 1. Clinically, Hhe has been classified as moderate
(15-30 µmol/l), intermediate (30-100 µmol/l), or severe
(>100 µmol/l), with normal values considered to be <15 µmol/l
(9). Mean plasma homocysteine levels in our animal models
were in the normal (control), IH, and SH range. In fact, homocysteine
levels in the SH group were very high (
200 µmol/l) but not beyond
those observed in certain inborn errors of metabolism
(19). Body weight and heart weight were reduced in rats
fed the SH diet compared with the same parameters in the control and IH
groups; however, the ratio of heart weight to body weight did not
differ significantly among groups. Chow intake was reduced in the SH
group when compared with the other two groups (data not shown).
Diastolic and systolic blood pressure and pulse pressure tended to
increase in the IH group and decrease in the SH group; however, no
significant differences were observed in these parameters.
|
Effects of IH and SH on basal LV function.
Isolated Langendorff-perfused heart preparations were used to examine
effects of Hhe on LV function. After the heart had stabilized under in
vitro conditions, the volume in the LV balloon was increased in 10-µl
increments, and intraventricular pressure was monitored for diastolic
pressure, peak systolic pressure, +dP/dtmax and
dP/dtmax. As shown in Fig.
1A, there was a shift of the
pressure-volume curve leftward and upward with Hhe; i.e., greater
elevations in diastolic pressure were observed at given balloon
volumes, with changes reaching statistical significance in the SH group
(as compared by ANOVA and post hoc analysis). Because diastolic
pressure was generally not detectable at balloon volumes <30 µl,
data shown in Fig. 1A include only those values obtained at
volumes
30 µl. Hearts from IH rats tended to have a greater
diastolic pressure than those from controls at balloon volumes of 70 and 80 µl; however, there was no significant difference between the
IH and control groups or between the IH and SH groups.
|
diastolic pressure) in each of the three groups are shown
in Fig. 1B. Values in Fig. 1B are presented as a
percentage of the maximum value to illustrate the observed differences.
Maximum values for developed pressure did not differ among the three
groups (control: 79.8 ± 9.2 mmHg, IH: 78.2 ± 5.6 mmHg, and
SH: 80.4 ± 6.7 mmHg). As indicated in Fig. 1B,
however, hearts from IH rats approached maximum developed pressure at
lower balloon volumes compared with hearts from controls (volumes
corresponding to 85% of maximum developed pressure as determined by
regression analysis were 51 ± 3 µl for controls and 36 ± 4 µl for IH rats). The response of hearts from the SH group did not
differ significantly from those of either the control or IH groups
(volume corresponding to 85% of maximum developed pressure in the SH
group was 38 ± 5 µl). Similar values were obtained when
monitoring +dP/dtmax and
dP/dtmax at increasing balloon volumes.
Maximum observed values for +dP/dtmax were
3,297 ± 301 mmHg/s for controls, 3,163 ± 174 mmHg/s for IH
rats, and 3,283 ± 229 mmHg/s for SH rats, whereas maximum values
obtained for
dP/dtmax were 1,608 ± 199 mmHg/s for controls, 1,644 ± 130 mmHg/s for IH rats, and
1,652 ± 118 mmHg/s for SH rats. Figure 1C shows the
relationship between diastolic pressure and developed pressure in
hearts isolated from each of the three groups. Values for developed
pressure in the SH group appeared to be shifted to the right of those
of controls; i.e., greater diastolic pressure was required to achieve
given levels of developed pressure; however, this relationship could not be tested statistically because of the nature of the data.
Coronary artery perfusion pressure was also monitored during the
experimentation in Langendorff-perfused hearts; a constant flow rate
of 7.0 ml · g
heart
1 · min
1 was
maintained in all preparations. Hhe produced a dose-dependent increase
in coronary perfusion pressure, with significant increases being
observed in both the IH and SH groups (80 ± 5, 110 ± 13, and 126 ± 9 mmHg in control, IH, and SH groups, respectively).
In summary, these results show that a duration of 10 wk of Hhe in
hypertensive rats is associated with a diastolic dysfunction that is
most likely the result of decreased myocardial compliance because the
maximum rate of relaxation (
dP/dtmax) observed
during examination of the pressure-volume relationship did not vary
significantly. There were no significant changes in baseline systolic
function. In addition, coronary perfusion pressure was significantly
increased in the IH and SH groups, indicating a possible increase in
coronary vascular resistance.
Effects of IH and SH on cardiac remodeling.
We examined the effects of elevated homocysteine levels on the myocyte
and nonmyocyte compartments in hypertensive hearts. Mean myocyte
diameter, measured at the level of the nucleus, did not vary
significantly among groups (data not shown). Perivascular collagen
deposition around 50- to 200-µm vessels (~10-15
vessels/section) was measured in picrosirius red-stained sections and
normalized to the luminal area. As shown in Table
3, perivascular collagen was increased
significantly in the IH and SH groups compared with controls. Figure 2,
A-C, shows representative
picrosirius red-stained sections from the three groups that demonstrate
the enhanced perivascular collagen deposition. Interstitial collagen
(measured in 30-35 fields/section) also tended to increase in the
IH and SH groups (Fig. 2, D-F); however, significant
differences were not observed (Table 3). We also measured the
hydroxyproline content in LV myocardium as a marker of collagen
concentration. As shown in Fig. 3, tissue
hydroxyproline levels increased with Hhe (control: 3.1 ± 0.52 µg/mg, IH: 4.3 ± 0.19 µg/mg, and SH: 5.27 ± 0.43 µg/mg). Figure 2, G-I, shows representative vessels
from each group after immunostaining for
-smooth muscle actin;
increasing medial thickness of the vessels was observed with increasing
levels of plasma homocysteine. As shown in Table 3, the wall-to-lumen
ratio tended to increase in both Hhe groups, reaching statistical
significance in the SH group.
|
|
|
| |
DISCUSSION |
|---|
|
|
|---|
We examined a novel link between Hhe and the burden of CVD. Because hypertension and Hhe are highly prevalent in the general population, the potentiation of adverse cardiac remodeling in hypertensive hearts by Hhe would be of great clinical importance. Our results indicate that IH and SH increase collagen levels in the hypertensive LV, cause coronary arteriolar wall thickening, and result in diastolic dysfunction.
Hhe has been linked to CVD in a number of previous reports. McCully (19) reported that SH resulting from inborn errors of metabolism results in vascular disease, and the prevalence of elevated plasma homocysteine levels increases from an estimated 5% in the general population to 13-47% in patients with symptomatic vascular disease (24). Retrospective and prospective studies have also shown an association between Hhe and CVD, including myocardial infarction and stroke (3, 23, 28). An interesting small clinical study by Blacher and coworkers (1), in which LV mass and plasma homocysteine levels were measured in 75 patients with end-stage renal disease undergoing hemodialysis, showed a highly significant positive correlation between echocardiographically measured LV mass index and plasma homocysteine, even after adjustment for age, sex, systolic blood pressure, and hematocrit. These data suggest that there is a relationship between Hhe and LVH.
Cardiomyocytes account for approximately one-third of the cells in the myocardium, whereas they occupy 75% of its volume (10, 41). A fibrillar collagen network forms the scaffolding that leads to coordinated myocyte contraction and myocardial force generation (39). Hypertension and other pressure-overload conditions, such as aortic stenosis, are characterized by a combination of myocyte hypertrophy and nonmyocyte cell proliferation with increased levels of collagen. The resultant pathological LVH is characterized by increased fibrosis disproportionate to myocyte hypertrophy (39). This leads initially to deleterious effects on diastolic function and subsequently to depressed systolic function due to interference with coordinated myocyte contraction. Hence, the amount of collagen in the myocardium seems to be a major determinant of the development of cardiac dysfunction in hypertension. The development of heart failure in the SHR model is characterized by increased expression of the precursors of types I and III collagen during the transition from stable cardiac hypertrophy to overt heart failure (2). In addition, Varo and coworkers (37) demonstrated that pathological LVH with myocardial fibrosis in the SHR model is characterized by increased LV collagen concentration, increased steady-state mRNA levels for tissue inhibitor of metalloproteinase-1 (TIMP-1), which regulates collagen degradation, and decreased activity of collagenase [matrix metalloproteinase-1 (MMP-1)], the rate-limiting step in extracellular collagen degradation (16, 40).
Structural analysis of the heart in patients with hypertension has also revealed changes in the coronary arterioles. Munhdenke and co-workers (21) showed that arterioles in patients with hypertensive heart disease have significant increases in medial area and perivascular collagen. They also showed that this remodeling is associated with reduced coronary reserve and clinical evidence of myocardial ischemia in the absence of epicardial coronary disease. In the SHR model that we used, medial thickening and perivascular fibrosis were shown to correlate with the degree of hypertension (11). This progressive cardiac remodeling and fibrosis have been postulated to increase the diffusion distance of oxygen and nutrients for myocytes, thereby contributing to myocyte dysfunction and death. Hence, these changes could lead to progressive myocyte loss, further worsening myocardial function (22, 27).
The human cardiovascular system has been shown to be limited in its
ability to metabolize homocysteine. Chen and coworkers (4)
determined the activity and protein levels of two major enzymes
involved in homocysteine metabolism, cystathionine
-synthase and
betaine homocysteine methyltransferase, in human heart
tissue from rejected donor hearts. The activities of both enzymes were minimal, indicating that the heart is limited in its ability to metabolize homocysteine via these pathways and thus depends primarily on the folate- and vitamin B12-dependent remethylation
(methionine synthase) pathway to clear homocysteine. Hence, it is
likely that the heart may be especially sensitive to the effects
of elevated plasma homocysteine levels.
We examined the effect of Hhe in SHRs using two diets based on homocystine (the disulfide form of homocysteine) supplementation. The diets were successful in elevating plasma homocysteine levels to the intermediate and severe ranges. The SH diet combined deficiencies of choline, methionine, and folate with homocystine supplementation and has been used previously in studies of carotid vascular disease (30). The plasma homocysteine level seen in the SH group in the present study was greater than that documented in the previous report (30), possibly because of the longer duration of dietary treatment. As discussed below, it is possible that folate deficiency played some role in the observed cardiac effects in the SH group; however, there was no significant decrease in hemoglobin or hematocrit after the 10-wk treatment period in our study (data not shown). Nonetheless, because Hhe in the general population frequently coexists with folate, vitamin B6, or vitamin B12 deficiency, this model has close parallels to the human condition. Blood pressure after the 10 wk of treatment showed a tendency to increase in the IH group [as reported previously (20)] and a tendency to decrease in the SH group. Similarly, as indicated in Fig. 1B, the shift of the curve showing effects of intraventricular balloon volume on LV developed pressure in the IH group was partially reversed in the SH group. The absence of a "concentration dependency" in terms of the effects of homocysteine on blood pressure and the "ventricular function curve" cannot be explained by current data, but it is possibly mediated by folate/methionine/choline deficiency-induced actions in SH that antagonized the effects of Hhe.
The results of our experiments demonstrated that Hhe is associated with a significant increase in perivascular collagen in hypertensive hearts. Interstitial collagen levels also tended to increase in both Hhe groups relative to controls, but this did not reach statistical significance. This parallels the actions of various chemokines known to affect myocardial remodeling (e.g., angiotensin II and aldosterone), which initiate myocardial collagen deposition in the perivascular region followed by an interstitial distribution (39, 40). The interstitial collagen deposition could represent replacement fibrosis after myocyte loss (39). In addition, we demonstrated an increase in the hydroxyproline content of LV myocardium, confirming that total collagen content increased with increasing plasma levels of homocysteine.
The sequence of events leading from elevated plasma homocysteine levels to increased collagen levels is a matter of speculation. Potential mechanisms include possible direct effects of homocysteine on fibroblast proliferation and function leading to increased collagen production or direct effects on collagen metabolism (35). Tyagi and coworkers (36) studied the effect of homocysteine on MMP activity in human coronary artery extracts. They showed a biphasic response, with an increase in collagenolytic activity at homocysteine concentrations <0.1 mM. In addition, homocysteine has been reported to induce TIMP-1 expression in vascular smooth muscle cells (32). Alternatively, high homocysteine levels may cause endothelial dysfunction and expression of adhesion molecules (12) followed by adhesion and activation of inflammatory cells, secretion of chemokines/growth factors, altered fibroblast function, and collagen deposition. The proximate events and signaling mechanisms that influence fibroblast, endothelial, or inflammatory cell function may include oxidative stress or signaling pathways such as protein kinase C and cell cycle proteins (38).
We examined the relation of the inflammatory cell response, specifically mast cell accumulation, to Hhe-induced cardiac remodeling in hypertensive hearts. Mast cells have been correlated with the severity of fibrosis in conditions such as scleroderma, idiopathic pulmonary fibrosis, and keloids (25). Li and co-workers (17) described an association between mast cells and the amount of myocardial fibrosis in transplanted human hearts. Another study (25) examined the relationship of mast cells to cardiac remodeling in the LV of SHRs and found significant increases in perivascular and interstitial collagen levels and an increased number of mast cells compared with normotensive controls. Therapy to decrease blood pressure was associated with a decrease in both collagen accumulation and mast cell number. We observed a dose-dependent increase in mast cells in hypertensive hearts subjected to Hhe that paralleled collagen accumulation. This interesting observation suggests that mast cells may play a role in cardiac remodeling secondary to Hhe in hypertensive hearts.
Hhe also promoted diastolic dysfunction in hearts of hypertensive rats.
The pressure-volume relationship was altered, showing an
upward/leftward shift with increasing levels of homocysteine. Data from
echocardiographic studies have shown that the LV chamber volume is
decreased slightly in hearts from SH rats compared with control rats;
however, this small change (diastolic diameter was decreased by ~8%,
data not shown) cannot account for the observed changes in the
pressure-volume curve. In contrast to the effect of Hhe on compliance,
the rate of relaxation expressed as
dP/dtmax did not differ significantly
among the groups. Diastolic dysfunction can result from increased
passive chamber stiffness or impaired myocardial relaxation
(6). Because there was no evidence of myocyte hypertrophy
or impaired myocardial relaxation, it seems likely that the Hhe-induced
diastolic dysfunction was caused by collagen accumulation and a
resulting increase in myocardial stiffness. This increase in stiffness
is a very significant finding because diastolic dysfunction accounts
for a significant percentage of patients with heart failure
(7), including those resulting from hypertensive heart disease.
The effect of Hhe on systolic function was also assessed in isolated perfused heart preparations. The relationship of peak developed LV pressure to LV balloon volume was shifted leftward with Hhe in the IH group; however, there was no change in the maximal pressure developed. This suggests that the shift in the curve was secondary to increased myocardial stiffness, which resulted in a given increase in volume, resulting in a greater increase in sarcomere length of the cardiomyocytes. These results suggest that the Hhe-induced increase in myocardial stiffness leads to a shift in the ventricular function curve without depression of the maximum achievable contractile response.
In summary, the results of this study suggest a novel mechanism for the contribution of Hhe to cardiovascular morbidity and mortality. Data from the SHR model indicate that the interaction of hypertension and Hhe leads to impaired diastolic function due to potentiation of the adverse myocardial and coronary vascular remodeling in hypertensive hearts. Further studies are required to explore the mechanisms of collagen accumulation and myocardial remodeling as well as the effects of interventions that decrease plasma homocysteine levels.
| |
ACKNOWLEDGEMENTS |
|---|
We thank the University of Arkansas for Medical Science Office of Grants and Scientific Publications for editorial assistance during the preparation of this manuscript.
| |
FOOTNOTES |
|---|
Address for reprint requests and other correspondence: J. Joseph, Div. of Cardiovascular Medicine, Dept. of Medicine, Slot 532, Univ. of Arkansas for Medical Sciences, 4301 W. Markham St., Little Rock, Arkansas 72205 (E-mail: josephjacob{at}uams.edu).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
August 29, 2002;10.1152/ajpheart.00475.2002
Received 6 June 2002; accepted in final form 20 August 2002.
| |
REFERENCES |
|---|
|
|
|---|
1.
Blacher, J,
Demuth K,
Guerin AP,
Vadez C,
Moatti N,
Safar ME,
and
London GM.
Association between plasma homocysteine concentrations and cardiac hypertrophy in end-stage renal disease.
J Nephrol
12:
248-255,
1999[Web of Science][Medline].
2.
Boluyt, MO,
O'Neill L,
Meredith AL,
Bing OH,
Brooks WW,
Conrad CH,
Crow MT,
and
Lakatta EG.
Alterations in cardiac gene expression during the transition from stable hypertrophy to heart failure: marked upregulation of genes encoding extracellular matrix components.
Circ Res
75:
23-32,
1994
3.
Boushey, CJ,
Beresford SA,
Omenn GS,
and
Motulsky AG.
A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intake.
JAMA
274:
1049-1057,
1995
4.
Chen, P,
Poddar R,
Tipa EV,
Dibello PM,
Moravec CD,
Robinson K,
Green R,
Kruger WD,
Garrow TA,
and
Jacobsen DW.
Homocysteine metabolism in cardiovascular cells and tissues: implications for hyperhomocysteinemia and cardiovascular disease.
Adv Enzyme Regul
39:
93-109,
1999[Web of Science][Medline].
5.
Chiariello, M,
Ambrosio G,
Cappelli-Bigazzi M,
Perrone-Filardi P,
Brigante F,
and
Sifola C.
A biochemical method for the quantitation of myocardial scarring after experimental coronary artery occlusion.
J Mol Cell Cardiol
18:
283-290,
1986[Web of Science][Medline].
6.
Colucci, WS,
and
Braunwald E.
Pathophysiology of heart failure.
In: Heart Disease, edited by Braunwald E.. Philadelphia, PA: Saunders, 1997.
7.
Dauterman, KW,
Massie BM,
and
Gheorghiade M.
Heart failure associated with preserved systolic function: a common and costly clinical entity.
Am Heart J
135:
S310-S319,
1998[Web of Science][Medline].
8.
Denhardt, DT,
Feng B,
Edwards DR,
Cocuzzi ET,
and
Malyankar UM.
Tissue inhibitor of metalloproteinases (TIMP, aka EPA): structure, control of expression and biological functions.
Pharmacol Ther
59:
329-341,
1993[Web of Science][Medline].
9.
Durand, P,
Prost M,
Loreau N,
Lussier-Cacan S,
and
Blache D.
Impaired homocysteine metabolism and atherothrombotic disease.
Lab Invest
81:
645-672,
2001[Web of Science][Medline].
10.
Frank, JS,
and
Langer JA.
The myocardial interstitium: its structure and its role in ionic exchange.
J Cell Biol
60:
586-601,
1974
11.
Hadjiisky, P.
Morphogenesis of the central and peripheral arteriopathies in the spontaneously hypertensive rat. I. Histological characteristics.
Paroi Arterielle
6:
169-181,
1980[Web of Science][Medline].
12.
Hofmann, MA,
Lalla E,
Lu Y,
Gleason MR,
Wolf BM,
Tanji N,
Ferran LJ, Jr,
Kohl B,
Rao V,
Kisiel W,
Stern DM,
and
Schmidt AM.
Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine model.
J Clin Invest
107:
675-683,
2001[Web of Science][Medline].
13.
Junqueira, LC,
Bignolas G,
and
Brentani RR.
Picrosirius staining plus polarization microscopy: a specific method for collagen detection in tissue sections.
Histochem J
11:
447-455,
1979[Web of Science][Medline].
14.
Kim, DH,
Akera T,
and
Kennedy RH.
Ischemia-induced enhancement of digitalis sensitivity in isolated guinea-pig heart.
J Pharmacol Exp Ther
226:
335-342,
1983
15.
Koren, MJ,
Devereux RB,
Casale PN,
Savage DD,
and
Laragh JH.
Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension.
Ann Intern Med
114:
345-352,
1991
16.
Laurent, GJ.
Dynamic state of collagen: pathways of collagen degradation in vivo and their possible role in regulation of collagen mass.
Am J Physiol Cell Physiol
252:
C1-C9,
1987
17.
Li, QY,
Raza-Ahmad A,
MacAulay MA,
Lalonde LD,
Rowden G,
Trethewey E,
and
Dean S.
The relationship of mast cells and their secreted products to the volume of fibrosis in posttransplant hearts.
Transplantation
53:
1047-1051,
1992[Web of Science][Medline].
18.
Majors, A,
Ehrhart LA,
and
Pezacka EH.
Homocysteine as a risk factor for vascular disease: enhanced collagen production and accumulation by smooth muscle cells.
Arterioscler Thromb Vasc Biol
17:
2074-2081,
1997
19.
McCully, KS.
Vascular pathology of hyperhomocysteinemia: implications for the development of arteriosclerosis.
Am J Pathol
56:
111-128,
1969[Web of Science][Medline].
20.
Miller, A,
Mujumdar V,
Shek E,
Guillot J,
Angelo M,
Palmer L,
and
Tyagi SC.
Hyperhomocyst(e)inemia induces multiorgan damage.
Heart Vessels
15:
135-143,
2000[Web of Science][Medline].
21.
Mundhenke, M,
Schwartzkopff B,
and
Strauer B.
Structural analysis of arteriolar and myocardial remodeling in the subendocardial region of patients with hypertensive heart disease and hypertrophic cardiomyopathy.
Virchows Arch
431:
265-273,
1997[Web of Science][Medline].
22.
Nicoletti, A,
and
Michel JB.
Cardiac fibrosis and inflammation: interaction with hemodynamic and hormonal factors.
Cardiovasc Res
41:
532-543,
1999
23.
Nygard, O,
Nordrehaug JE,
Refsum H,
Ueland PM,
Farstad M,
and
Vollset SE.
Plasma homocysteine levels and mortality in patients with coronary artery disease.
N Engl J Med
337:
230-236,
1997
24.
Nygard, O,
Vollset SE,
Refsum H,
Brattstrom L,
and
Ueland PM.
Total homocysteine and cardiovascular disease.
J Intern Med
246:
425-454,
1999[Web of Science][Medline].
25.
Panizo, A,
Mindan FJ,
Galindo MF,
Cenarruzabeitia E,
Hernandez M,
and
Diez J.
Are mast cells involved in hypertensive heart disease?
J Hypertens
13:
1201-1208,
1995[Web of Science][Medline].
26.
Roberts, ISD,
and
Benchley PEC
Mast cells: the forgotten cells of renal fibrosis.
J Clin Pathol
53:
858-862,
2000
27.
Sabbah, HN,
Sharov VG,
Lesch M,
and
Goldstein S.
Progression of heart failure: a role for interstitial fibrosis.
Mol Cell Biochem
147:
29-34,
1995[Web of Science][Medline].
28.
Schnyder, G,
Orf M,
Pin R,
Flapper Y,
Lange H,
Eberle FR,
Meier B,
Tru SG,
and
Hess OM.
Decreased rate of coronary restenosis after lowering of plasma homocysteine levels.
N Engl J Med
345:
1593-1600,
2001
29.
Sigusch, HH,
Campbell SE,
and
Weber KT.
Angiotensin II induced myocardial fibrosis in rats: role of nitric oxide, prostaglandins and bradykinin.
Cardiovasc Res
31:
546-554,
1996[Web of Science][Medline].
30.
Southern, FN,
Cruz N,
Fink LM,
Cooney CA,
Barone GW,
Eidt JF,
and
Moursi MM.
Hyperhomocysteinemia increases intimal hyperplasia in a rat carotid endarterectomy model.
J Vasc Surg
28:
909-918,
1998[Web of Science][Medline].
31.
Switzer, B.
Determination of hydroxyproline in tissue.
J Nutr Biochem
2:
229-231,
1991[Web of Science].
32.
Torres, L,
Garcia-Trevijano ER,
Rodriguez JA,
Carretero MV,
Bustos M,
Fernandez E,
Eguinoa E,
Mato JM,
and
Avila MA.
Induction of TIMP-1 expression in rat hepatic stellate cells and hepatocytes: a new role for homocysteine in liver fibrosis.
Biochim Biophys Acta
1455:
12-22,
1999[Medline].
33.
Tsai, JC,
Perrella MA,
Yoshizumi M,
Hsieh CM,
Haber E,
Schlegel R,
and
Lee ME.
Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis.
Proc Natl Acad Sci USA
91:
6369-6373,
1994
34.
Tsai, JC,
Wang H,
Perrella MA,
Yoshizumi M,
Sibinga NE,
Tan LC,
Haber E,
Chang TH,
Schlegel R,
and
Lee ME.
Induction of cyclin A gene expression by homocysteine in vascular smooth muscle cells.
J Clin Invest
97:
146-153,
1996[Web of Science][Medline].
35.
Tyagi, SC.
Homocyst(e)ine and heart disease: pathophysiology of extracellular matrix.
Clin Exp Hypertens
21:
181-198,
1991.
36.
Tyagi, SC,
Smiley LM,
Mujumdar VS,
Clonts B,
and
Parker JL.
Reduction-oxidation (redox) and vascular tissue level of homocyst(e)ine in human coronary atherosclerotic lesions and role in extracellular matrix remodeling and vascular tone.
Mol Cell Biochem
181:
107-116,
1998[Web of Science][Medline].
37.
Varo, N,
Iraburu MJ,
Varela M,
Lopez B,
Etayo JC,
and
Diez J.
Chronic AT1 blockade stimulates extracellular collagen type I degradation and reverses myocardial fibrosis in spontaneously hypertensive rats.
Hypertension
35:
1197-1202,
2000
38.
Wang, G,
Siow YL,
and
Oh K.
Homocysteine stimulates nuclear factor kappaB activity and monocyte chemoattractant protein-1 expression in vascular smooth-muscle cells: a possible role for protein kinase C.
Biochem J
352:
817-826,
2000[Web of Science][Medline].
39.
Weber, KT,
and
Brilla CG.
Pathological hypertrophy and cardiac interstitium: fibrosis and the renin-angiotensin-aldosterone system.
Circulation
83:
1849-1865,
1991
40.
Woessner, JF, Jr.
Matrix metalloproteinases and their inhibitors in connective tissue remodeling.
FASEB J
131:
2145-2154,
1991.
41.
Zak, R.
Cell proliferation during cardiac growth.
Am J Cardiol
31:
211-219,
1973[Web of Science][Medline].
This article has been cited by other articles:
![]() |
M. Herrmann, O. Taban-Shoma, U. Hubner, A. Pexa, H. Kilter, N. Umanskaya, R. Hans Straub, M. Bohm, and W. Herrmann Hyperhomocysteinemia and Myocardial Expression of Brain Natriuretic Peptide in Rats Clin. Chem., April 1, 2007; 53(4): 773 - 780. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Herrmann, S. Muller, I. Kindermann, L. Gunther, J. Konig, M. Bohm, and W. Herrmann Plasma B vitamins and their relation to the severity of chronic heart failure Am. J. Clinical Nutrition, January 1, 2007; 85(1): 117 - 123. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Herrmann, O. Taban-Shomal, U. Hubner, M. Bohm, and W. Herrmann A review of homocysteine and heart failure Eur J Heart Fail, October 1, 2006; 8(6): 571 - 576. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Joseph, R. H. Kennedy, S. Devi, J. Wang, L. Joseph, and M. Hauer-Jensen Protective role of mast cells in homocysteine-induced cardiac remodeling Am J Physiol Heart Circ Physiol, May 1, 2005; 288(5): H2541 - H2545. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. H. Kennedy, M. Hauer-Jensen, and J. Joseph Cardiac function in hearts isolated from a rat model deficient in mast cells Am J Physiol Heart Circ Physiol, February 1, 2005; 288(2): H632 - H637. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Cesari, M. Zanchetta, A. Burlina, L. Pedon, G. Maiolino, D. Sticchi, A. C. Pessina, and G. P. Rossi Hyperhomocysteinemia Is Inversely Related With Left Ventricular Ejection Fraction and Predicts Cardiovascular Mortality in High-Risk Coronary Artery Disease Hypertensives Arterioscler Thromb Vasc Biol, January 1, 2005; 25(1): 115 - 121. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. H. Kennedy, R. Owings, N. Shekhawat, and J. Joseph Acute negative inotropic effects of homocysteine are mediated via the endothelium Am J Physiol Heart Circ Physiol, August 1, 2004; 287(2): H812 - H817. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Sundstrom, L. Sullivan, J. Selhub, E. J Benjamin, R. B D'Agostino, P. F Jacques, I. H Rosenberg, D. Levy, P. W.F Wilson, and R. S Vasan Relations of plasma homocysteine to left ventricular structure and function: the Framingham Heart Study Eur. Heart J., March 2, 2004; 25(6): 523 - 530. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Joseph, L. Joseph, N. S. Shekhawat, S. Devi, J. Wang, R. B. Melchert, M. Hauer-Jensen, and R. H. Kennedy Hyperhomocysteinemia leads to pathological ventricular hypertrophy in normotensive rats Am J Physiol Heart Circ Physiol, July 11, 2003; 285(2): H679 - H686. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |